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Elimination of lymphatic filariasis (LF) in the Pacific Island Countries and Territories (PICT) has been defined as <0.1% circulating
filarial antigen (CFA) prevalence in children born after the implementation of successful mass drug administrations (MDAs). This
research assessed the feasibility of CFA and antibody testing in three countries; Tonga, Vanuatu, and Samoa. Transmission is
interrupted in Vanuatu and Tonga as evidenced by no CFA positive children and a low antibody prevalence and titre. Transmission
is ongoing in Samoa with microfilaraemic (Mf) and CFA positive children and a high antibody prevalence and titre. Furthermore,
areas of transmission were identified with Mf positive adults, but no CFA positive children. These areas had a high antibody
prevalence in children. In conclusion, CFA testing in children alone was not useful for identifying areas of residual endemicity in
Samoa. Thus, it would be beneficial to include antibody serology in the PICT surveillance strategy.
1. Introduction
Lymphatic filariasis (LF), a mosquito-transmitted parasitic
disease caused by the filarial nematodesWuchereria bancrofti,
Brugia malayi, and Brugia timori, is classified as a neglected
tropical disease (NTD) that is endemic in many parts of
the world including the South Pacific [1–3]. The Global
Elimination Programme to eliminate LF (GPELF) began
in the late 1990s, and the Pacific counterpart of GPELF,
formed in 1999 under the auspices of the World Health
Organization (WHO), was named the Pacific Programme
for the Elimination of Lymphatic Filariasis (PacELF) [4, 5].
PacELF resolved to eliminate LF as a public health problem
in the Pacific using mass drug administrations (MDAs) [5].
Elimination of LF was defined as <1% circulating filarial
antigen (CFA) prevalence of the population and <0.1% CFA
prevalence in children born after the implementation of
MDAs [6].
Sixteen of the 22 countries falling under the jurisdiction
of PacELF were classified as endemic for LF following
baseline prevalence surveys. They were American Samoa, the
Cook Islands, the Federated States of Micronesia, Fiji, French
Polynesia, Kiribati, the Marshall Islands, New Caledonia,
Niue, Palau, Papua New Guinea, Samoa, Tonga, Tuvalu,
Vanuatu, andWallis and Futuna [7]. The Cook Islands, Niue,
Vanuatu, and Tonga have reached <1% CFA prevalence of
the population following five rounds of MDA and are now
implementing activities to ensure that transmission has been
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interrupted and to detect any remaining and/or new foci
of transmission [8]. The challenge for this phase of the LF
programme is to find a suitable strategy for surveillance in
those countries that have reached the target threshold.
Recently, child transmission surveys (CTS) have been
proposed as a potential method for surveillance in the South
Pacific as part of the “draft LF active surveillance strategy for
the Pacific Island Countries and Territories (PICT)” [7]. This
method relies on detecting CFA positive children in either
school-based or community-based surveys. The strategy was
based on the preapproved LF diagnostic assays available and
took into consideration resource and funding constraints
[7]. Upon detection of a CFA positive child, using the field
immunochromatographic test (ICT), surrounding residents
(200m radius or 24 houses) would be tested to identify the
microfilaraemic (Mf) positive case from the child’s house of
residence [7]. Since drafting the surveillance strategy, three
South Pacific countries have finished their CTS, either alone
or in conjunction with post-MDA prevalence surveys. The
CTS was completed in two countries which had entered
surveillance mode, Tonga and Vanuatu, and Samoa, where
transmission was ongoing [8].
As the prevalence of LF declines, the sensitivities of the
gold standards, which measure Mf and CFA, also decrease
[9–13], potentially making these assays less useful during this
stage of the LF elimination programme [14–16]. Antibody
responses to LF exposure have been suggested as an ideal
immunological measurement for identifying areas of residual
endemicity in future surveillance campaigns [9, 14, 17–19].
Previous studies demonstrated that antibody production in
response to LF exposure occurs during the first few years of
life [20]. Therefore, children born after the cessation of LF
transmission should be antibody negative [17, 21–27]. One
standardised diagnostic tool for the detection of antibodies
is the Filariasis Cellabs Enzyme Linked Immunosorbent
Assay (CELISA). This diagnostic assay measures antifilarial
IgG4 and is adaptable for both serum samples and filter
paper samples with little interlaboratory variation [28,
29]. Antibody serology can be used in conjunction with
seroprevalence mapping, which has been demonstrated to be
useful for visualising problem areas where exposure occurs
[30].
Filariasis control began in Tonga in 1977, and by
1999, when Tonga joined PacELF, the CFA prevalence
was recorded as 2.7% (http://www.wpro.who.int/pacelf/
programmes/ton/PacELF+Activities+to+Date.htm). MDA
rounds were completed annually in Tonga for five years from
2001 to 2005 with reported coverage rates of 79%, 84%,
91%, 86%, and 85%, respectively, [8]. Following the fifth
round of MDA, Tonga recorded an overall CFA prevalence of
0.4% and, therefore, completed its CTS in 2007. The results
are presented in this paper.
By 2005, Vanuatu had completed its fifth round
ofMDA (http://www.wpro.who.int/pacelf/programmes/van/
activities.htm). The annual rounds were from 2000 to 2004
with reported coverage rates of 83%, 84%, 84%, 87%,
and 85%, respectively, [8]. Following the final round of
MDA in 2005, countrywide CFA prevalence was 0.32%,
with no detectable Mf positives (Vanuatu country report,
unpublished data) [8]. Consequently, Vanuatu completed its
CTS in 2007, the results of which are presented in this paper.
Samoa has a long history of filariasis control; initial
filariasis surveys began as early as the 1920s, with attempts
at control programmes in the 1940s [4]. In 1966, MDAs
began and Samoa completed 10 rounds of MDA before the
establishment of PacELF [31, 32]. In 1999, Samoa was the
first country to implement the new MDA regimen using a
combination of diethylcarbamazine citrate (DEC) and alben-
dazole [4]. A further six rounds of MDA were completed
from 1999 to 2006. The reported MDA coverage for the five
rounds conducted from 1999 to 2003 was 90%, 57%, 68%,
60%, and 80%, respectively, [8]. In 2004, a stratified cluster
nationwide survey demonstrated an overall Mf prevalence
of 0.4% with a CFA prevalence of 1.1%. This corresponded
to a 75.6% reduction in CFA positive individuals since the
beginning of the new national programme in 1999 [4, 5].
The results from the follow-up survey in 2007 are presented
in this paper in conjunction with the 2007 CTS.
The aim of this research was to determine if the presence
of CFA positive children alone accurately reflected a cessation
of LF transmission, as assumed in the draft surveillance
strategy, or if it was necessary to complement CFA testing
with antibody serology using the Filariasis CELISA. By
doing so, we help contribute to defining a cessation of LF
transmission and early detection of possible resurgence as
part of active surveillance. This will assess the potential of
the Filariasis CELISA to be incorporated into the repertoire
of available LF diagnostic assays currently used in LF
elimination programmes. Serological mapping could then be
used to easily identify and visualise areas where exposure is
ongoing and where further investigations could be required
by the country LF programme managers [33].
2. Materials and Methods
2.1. Study Population. Three South Pacific countries, Samoa,
Tonga, and Vanuatu, participated in the study in 2007. The
study was conducted under Human Ethics Approval number
H1423, as approved by the James Cook University Research
Human Ethics Committee.
2.1.1. Samoa. The post-MDA prevalence survey was a
national survey conducted by health district, across both
Savai’i and Upolu using the stratified cluster method. Strati-
fied cluster sampling was performed by dividing the country
into implementation units (IUs) within which villages were
chosen randomly [6]. Within the village, a minimum of five
households were randomly chosen. Participants of any age
were asked to register, and blood samples were taken. All
participants were bled for ICT testing and those that tested
ICT positive were rebled for Mf testing. Filter paper samples
were also collected from children aged 5 to 10 years for
antibody serology. Overall, the survey included 6648 people,
with 2315 children ≤10 years. Of these children, 1045 were
included in antibody testing.
2.1.2. Tonga. CTS carried out in Tonga was in accordance
with the “draft LF active surveillance strategy for the PICT”
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using the school-based approach [7], but with the addition
of antibody serology. Blood collection occurred in primary
schools across the islands of ‘Eua, Ha’apai, and Vava’u.
Overall, 797 children aged 5 to 6 years participated in the
study. All participants were bled for ICT testing and those
that tested ICT positive were rebled for Mf testing. Filter
paper samples were also collected for antibody serology.
2.1.3. Vanuatu. A total of 3840 children aged 5 to 6 years
were bled across the country in accordance with the CTS
outlined in the “draft LF active surveillance strategy for the
PICT” using the community-based approach [7], but with
the addition of antibody serology. These children were bled
for ICT and those positive were bled for Mf testing. Filter
paper samples were also collected for antibody serology.
2.2. Blood Collection. Following registration and informed
verbal consent, approximately 220 μL of blood was collected
by fingerprick. One hundred microlitres was used for CFA
testing in the field. If the ICT test was positive, 60 μL was used
to make a three-line thick blood smear for Mf examination.
The remaining blood was soaked onto the six protrusions
of a Tropbio filter paper disc, each holding 10 μL of blood
(Tropbio Pty Ltd, QLD, Australia). The filter paper disc
was dried, placed in ziplock bags, and transported back to
Australia for storage at −20◦C until testing for antifilarial
antibodies.
2.3. Circulating Filarial Antigen Testing. The field test to
detect CFA was the NOW filariasis Immunochromato-
graphic test (ICT) and performed according to the manufac-
turer’s instructions as previously described (Binax, Portland,
ME, USA) [34]. Briefly, the collected 100 μL of blood was
transferred onto the absorbent pad using the capillary tube
and the result was read at exactly 10 minutes, according to
the manufacturer’s instructions, and recorded as positive,
negative, or invalid. Positives (referred to as CFA positive)
were rebled for Mf examination.
2.4. Microfilaremia Testing. Blood taken from a fingerprick
was smeared into three lines, approximately 20 μL thick,
onto a microscope glass slide using a capillary as previously
described [35]. The slides were left to dry for 48 hours
then wrapped for transport. In the laboratory of each
country, each slide was stained in 10% Giemsa stain (20
minutes), washed in water, dried, then coverslipped. The
slide was examined under the microscope (×200), and Mf
were recorded. The number of Mf per mL of blood was
calculated based on the initial 60 μL volume. Blood collection
for Mf testing in Vanuatu and Tonga occurred between 2200
and 0100 hours. Blood collection for Mf testing in Samoa
occurred between 0800 and 2000 hours according to peak
levels of Mf and biting tendencies of Aedes polynesiensis [36].
2.5. Antibody Testing with the Filariasis CELISA. Antifilarial
IgG4 antibodies were detected using the Filariasis CELISA
kit (Cellabs Pty Ltd, Manly, Australia). One protrusion
of filter paper was eluted overnight at 4◦C in 500 μL of
sample diluent. The following morning, the elution was
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Figure 1: Prevalence rates of the diagnostic parameters: Mf,
CFA, and antibody in children. There was a significantly lower
antibody (Ab) prevalence in children in Vanuatu and Tonga and
a significantly higher antibody prevalence in children in Samoa
(χ2 = 549.3; df = 3; P < 0.001). There were no Mf or CFA positive
children detected in either Vanuatu or Tonga.
thoroughly vortexed and assayed in duplicate, according
to the manufacturer’s instructions. The washing steps were
performed with an automated plate washer (MultiDrop
Combi nL, Pathtec, VIC, Australia) using 200 μL per well.
Plates were read at a dual wavelength of 450 nm and 650 nm
with aMultiskan EX Type 355 Primary V.2.1-0 (Pathtec, VIC,
Australia) using the software Labsystems Genesis Version
3.00 (Pathtec, VIC, Australia). Negative samples were defined
as OD value <0.260, and positive samples were defined as OD
value ≥0.400 [28]. Samples with values between these OD
values were repeated, in accordance with the manufacturer’s
instructions, and if the OD value was <0.400, they were
considered negative. Antibody prevalence was based on
positive/negative reactivity of the samples. Antibody titres
were assumed to correspond to the OD absorbance value
[37].
2.6. Statistical Analysis and Prevalence Mapping. All data
was entered into SPSS Statistical Software Package Ver-
sion 17.0. Prevalence rates were calculated using the
descriptive options in SPSS, and 95% Confidence Interval
(CI) was calculated using the JavaStat binomial software
(http://statpages.org/confint.html) and included in the fig-
ures. Chi-squared test was used to investigate the difference
in prevalence rates among countries and health districts
in Samoa. The Kruskall-Wallis test for nonparametric data
was used to compare the OD absorbance values (antibody
titres) among the three countries. Prevalence ofMf, CFA, and
antibody in Samoa was mapped using CorelDRAW.
3. Results
3.1. Study Population. In Vanuatu and Tonga, all children
tested negative for CFA, whereas in Samoa there were Mf and
CFA positive children detected (Figure 1). This was coupled
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Figure 2: Differences in antibody titre in antibody-positive children
residing in Samoa, Tonga, and Vanuatu. Of those children who were
antibody positive, there was a significantly higher average antibody
titre in Samoa than Vanuatu and Tonga (χ2 = 41; df = 2; P = 0).
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Figure 3: Mf, CFA, and antibody prevalence across the health
districts in Samoa. Leulumoega 1 recorded a significantly higher Mf
(∗), CFA (∗), and antibody (Ab) prevalence in children (∗) than
the other districts (χ2 = 46.9; df = 6; P < 0.001), (χ2 = 124.9;
df = 6; P < 0.001), (χ2 = 20.6; df = 6; P < 0.001). Similarly,
Palalui recorded a significantly high antibody (Ab) prevalence (∗∗)
in children (χ2 = 20.6; df = 6; P < 0.001).
with a significantly lower antibody prevalence recorded for
both Vanuatu (6.0%) and Tonga (6.3%) when compared to
Samoa (30.7%) (P < 0.001, Figure 1). In addition, of those
children who were antibody positive, there was a significantly
higher average antibody titre in Samoa than Vanuatu and
Tonga (P = 0, Figure 2). Consequently in Samoa, the overall
significantly higher antibody prevalence and titre, coupled
with Mf and CFA positive children, was further analysed
by health district to identify potential residual areas of
endemicity.
3.1.1. Samoa. When analysing the data by health district,
Leulumoega 1, on Upolu, had a significantly higher Mf
prevalence (2%) (P < 0.001) and CFA prevalence (7.3%)
(P < 0.001, Figure 3). Furthermore, including Palalui,
Leulumoega 1 had a significantly higher antibody prevalence
in children (44.9%) (P < 0.001, Figure 3). There were three
health districts with detectable Mf positive adults, but no
CFA positive children (Safotu (0.2%) and Tuasivi (0.3%)
on Savai’i and Leulumoega 2 (0.4%) on Upolu). In these
areas, Mf prevalence exceeded 0.1%, the defined threshold
for ongoing transmission [6], and the antibody prevalence in
children exceeded 20%. Prevalence for the three parameters
was easily visualised on the geographical maps, including
residual endemic areas in the aforementioned districts
(Figure 4).
When analysing the data for children only, Upolu main-
tained a significantly higher CFA prevalence (P = 0.043), yet
no differences were observed for Mf prevalence between the
islands (P = 0.218, Figure 5). For the health districts, Mf
positive children were found only in Leulumoega 1, which
had a significantly higher antibody prevalence (Figure 3)
and the highest CFA prevalence, although not significantly
higher than the other villages with CFA positive children
(P = 0.271). Lufilufi and Palalui were the other 2 villages
with CFA-positive children (Figure 5).
4. Discussion and Conclusions
Active LF surveillance requires accurate and sensitive diag-
nostic assays to detect residual areas of endemicity and
resurgence early. The current draft LF active surveillance
strategy for the PICT [7] relies solely on CFA testing in chil-
dren, since the use of antibody serology is not yet currently
approved [6]. This is due to the need for standardisation,
which can now be achieved using the commercially available
Filariasis CELISA (Cellabs Pty Ltd). It was the aim of this
research to assess the validity of the current surveillance
strategy and if incorporating antibody serology would be
advantageous in the PICT. The first aim of the research was
partially addressed, but until long-term monitoring of the
outcomes of the elimination programme occurs, the strategy
will continue to be dynamic to meet individual country
needs.
The data indicated the cessation of LF transmission in
both Tonga and Vanuatu and ongoing LF transmission in
Samoa. In Tonga and Vanuatu, there were no detectable CFA
positive children coupled with a significantly low antibody
prevalence and titre. Identification of Mf and CFA positive
children in Samoa was coupled with a significantly higher
antibody prevalence and titre. For Vanuatu and Tonga,
the higher value of antibody prevalence (6%) versus the
CFA prevalence (0%) is a reflection of the sensitivity and
specificity of the Filariasis CELISA for filter paper sampling.
When using filter paper samples, the Filariasis CELISA has a
positive predictive value (PPV) of 60% (95% CI = 43–75)
[28]. This means that a false positive is expected at a rate
of approximately 40% (95% CI = 25% to 57% of the time)
[28]. Filter paper samples have inherent higher OD values
[38], but it would be disadvantageous to use serum for wide-
scale programmatic sampling because of the difficulties with
collection and storage [28]. The higher PPV of the Filariasis
Journal of Tropical Medicine 5
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Figure 4: Serological mapping for Mf, CFA, and antibody prevalence across Samoa. Geographical mapping allows quick reference to
suspected problem areas or “hot spots” of residual endemicity.
CELISA does not impact on the usefulness of the diagnostic
assay from a programmatic perspective, since recent research
has demonstrated the use of the assay for identifying clusters
of exposed children [39]. It could be suggested that it would
be appropriate for the country programme managers to
follow up any identified clusters of exposed children with
a more in-depth serological study using the gold standard
serum. This would be on a smaller and more manageable
scale than the programmatic survey.
Previous studies in Egypt, where the vector Culex sp. is
endemic [40], suggest a <2% antibody prevalence in first-
year primary school children as a threshold for elimination
[25]. This study did indicate the potential necessity for
different threshold targets for other endemic areas. The
data presented here does not concur with a 2% antibody
prevalence threshold for interruption of transmission in the
PICT since both Vanuatu and Tonga recorded prevalence
rates of 6% and transmission was interrupted. However,
the studies in Egypt used serum samples with laboratory-
based ELISAs, not filter paper samples with the commercial
Filariasis CELISA.
The detection of ongoing transmission in Samoa was
further analysed by each health district to assess if the current
surveillance strategy could identify problem areas. CFA test-
ing alone in children (CTS) was not adequate for identifying
all of the key residual areas of endemicity in Samoa. There
were three health districts with detectable Mf positive adults,
but no CFA positive children, where transmission would
likely be occurring. This is because in these health districts
Mf prevalence exceeded 0.1%, the recommended threshold
by WHO for the interruption of transmission [6] and spatial
clustering of LF has been previously identified [39]. The
health districts identified were Safotu and Tuasivi on the
island of Savai’i and Leulumoega 2 on the island of Upolu.
In these health districts, the antibody prevalence in children
exceeded 20%, an observation compatible with ongoing
exposure. Very importantly, it must be emphasised that these
health districts would not have been detected as areas of
residual or reemerging infection based on CFA testing in
children alone and would have been missed if the proposed
WHO surveillance programme using ICT testing was in
place. These significant foci were only identified because
6 Journal of Tropical Medicine
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Figure 5: Mf, CFA, and antibody prevalence in children ≤10 years
only across the health districts in Samoa. Similar to the data across
all ages groups, Upolu had a significantly higher CFA prevalence
in children than Savai’i (χ2 = 4.086; df = 1; P = 0.043). No
differences for Mf prevalence were observed between the two island
groups (χ2 = 1.514; df = 1; P = 0.218). Similarly, no significant
differences for Mf prevalence were observed among the health
districts (χ2 = 10.694; df = 6; P = 0.098), since Mf positive
children were identified only in Leulumoega 1. Complementing
this result, Leulumoega 1 recorded a significantly higher antibody
(Ab) prevalence (∗) than the other districts (χ2 = 20.6; df = 6;
P < 0.001). The health districts of Aua, Leulumoega 2, Safotu,
and Tuasivi recorded no CFA positive children. There were no
significant differences for CFA prevalence in children among the
health districts (χ2 = 2.612; df = 2; P = 0.271).
antibody serology was included in the testing protocol.
Therefore, it would be beneficial to strengthen the current
strategy surveillance strategy by including antibody serology.
In Samoa, the identification of Mf and CFA positive chil-
dren is indicative of ongoing transmission, which is further
evidenced by a significantly higher antibody prevalence and
titre in children. These findings support previous studies
whereby Samoa exceeded 1% CFA prevalence following five
rounds of MDA [8]. The reasons for ongoing transmission
in Samoa are yet to be ascertained, but it is crucial that these
are addressed in order for LF elimination to be successful.
It has been suggested that lack of directly observed therapy
(DOT), lack of compliance, and lack of vector control could
all be contributing factors [8, 31, 41, 42]. Recent research has
indicated the potential for vector control in Samoa which
will have a positive impact on the Samoan LF elimination
programme [39]. The seroprevalence maps in the current
study could provide the Samoan LF programme managers
with a starting point to further investigate residual endemic
areas and potentially incorporate vector control.
In addition, the results from the current study indicate
that antibody prevalence thresholds need to be comple-
mented with analysing antibody titres, since the low antibody
prevalence in Tonga and Vanuatu was coupled with a signif-
icantly low antibody titre in positive children. Collectively,
low prevalence and low titre (with no detectable antigen-
positive children) suggest an interruption of transmission.
During active surveillance mode, the detection of an area
with low antibody prevalence but high antibody titre could
require further investigation.
In conclusion, transmission of LF has been interrupted
in Tonga and Vanuatu as evidenced by no detectable
CFA positivity in children and significantly low antibody
prevalence and titres. Ongoing transmission of LF is evident
in Samoa based on the presence of Mf/CFA positive children
and a significantly high antibody prevalence and titres. Most
importantly, key residual areas of endemicity, which can also
be observed by seroprevalence mapping, would have been
overlooked when testing for CFA positivity alone in children.
This holds promise for future incorporation of antibody
prevalence mapping in the current surveillance strategy for
the PICT.
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